Edition:
United States

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

15.65USD
21 Sep 2018
Change (% chg)

$-0.35 (-2.19%)
Prev Close
$16.00
Open
$16.00
Day's High
$16.02
Day's Low
$15.45
Volume
168,540
Avg. Vol
44,090
52-wk High
$24.00
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Selecta Biosciences Qtrly Loss Per Share $0.88
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 REVENUE $100,000 VERSUS $2.9 MILLION.Q4 REVENUE VIEW $5.3 MILLION -- THOMSON REUTERS I/B/E/S.PHASE 1 CLINICAL TRIAL OF SEL-403 FOR MESOTHELIOMA INITIATED.REPORTS YEAR-END 2017 CASH OF $97 MILLION AND REITERATES RUNWAY THROUGH MID-2019.QTRLY LOSS PER SHARE $0.88.  Full Article

Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018
Monday, 8 Jan 2018 08:44am EST 

Jan 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING.SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019.  Full Article

Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy
Tuesday, 2 Jan 2018 08:05am EST 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY.SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018.  Full Article

Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End
Tuesday, 2 Jan 2018 08:00am EST 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN.SELECTA BIOSCIENCES INC - CEO WERNER CAUTREELS PLANS RETIREMENT AT END OF 2018.SELECTA BIOSCIENCES INC - OMID FAROKHZAD APPOINTED CHAIRMAN OF BOARD.SELECTA BIOSCIENCES INC - EXPECTS CAUTREELS TO REMAIN A MEMBER OF BOARD FOLLOWING HIS RETIREMENT.  Full Article

Selecta Biosciences announces Q3 loss per share $0.66
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces third quarter 2017 financial results and provides corporate update.Q3 revenue $100,000 versus $1.0 million.Q3 revenue view $383,000 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.66.Selecta -‍ Cash, cash equivalents, short-term deposits, investments & restricted cash sufficient to fund expenditure requirements into mid-2019​.  Full Article

Selecta Biosciences names John Leaman chief financial officer
Thursday, 26 Oct 2017 08:00am EDT 

Oct 26 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces important additions to senior leadership team.Selecta Biosciences Inc - ‍Appointment of John Leaman as company's new chief financial officer and head of corporate strategy​.  Full Article

Selecta Biosciences files for mixed shelf of up to $‍​200 mln - SEC Filing
Friday, 11 Aug 2017 07:55am EDT 

Aug 11 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences Inc files for mixed shelf of up to $‍​200 million - SEC Filing.  Full Article

Selecta Biosciences Q2 loss per share $0.85
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Selecta Biosciences Inc :Selecta biosciences announces second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.85.Q2 revenue $100,000 versus $2.0 million.Q2 revenue view $557,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.90 -- Thomson Reuters I/B/E/S.Selecta biosciences - expects cash, cash equivalentswill be sufficient to fund co's operating expenses and capital expenditure requirements into 2019.  Full Article

Selecta Biosciences files for offering of 3.2 mln shares by selling stockholders
Thursday, 13 Jul 2017 06:18am EDT 

July 13 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences files shelf prospectus relating to proposed offering and resale of 3.2 million shares of common stock by selling stockholders - SEC filing.  Full Article

Vivo Capital VIII reports 5.1 pct passive stake in Selecta Biosciences
Friday, 30 Jun 2017 04:55pm EDT 

June 30 (Reuters) - Vivo Capital VIII Llc::Vivo Capital VIII Llc reports 5.1 percent passive stake in Selecta Biosciences Inc, as of June 26, 2017 - SEC filing.  Full Article

Exclusive: KKR preps vending machine operator Selecta for $1 billion IPO - sources

FRANKFURT/LONDON Buyout group KKR has started preparations to list vending machine operator Selecta on the Swiss bourse as soon as the fourth quarter of 2018, people close to the matter said, adding to a flurry of major listings in the country.